Aldeyra Therapeutics, Inc.ALDXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.92% | +0.49% | +0.80% | +1.06% | +1.00% |
| Weighted Average Shares Diluted Growth | +0.92% | +0.49% | +0.80% | +1.06% | +1.00% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -2505.25% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -2505.25% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -20.34% | -29.48% | -34.04% | -32.59% | -33.68% |
| Book Value per Share Growth | -31.45% | -41.02% | -44.37% | -44.35% | -42.70% |
| Debt Growth | -3.53% | -2.26% | -0.58% | -0.51% | -0.45% |
| R&D Expense Growth | +78.71% | +240.37% | +20.05% | -43.18% | -56.35% |
| SG&A Expenses Growth | +42.78% | +8.68% | -6.42% | -45.24% | -30.46% |